• Asian Pacific Journal of Cancer Prevention
• /
• 제15권11호
• /
• pp.4567-4570
• /
• 2014

Background: This systemic analysis was conducted to evaluate the efficacy and safety of pemetrexed based chemotherapy in treating patients with metastatic breast cancer as first or second line chemotherapy. Methods: Clinical studies evaluating the efficacy and safety of pemetrexed based regimens on response and safety for patients with breast cancer were identified using a predefined search strategy. Pooled response rate (RR) of treatment were calculated. Results: In first line pemetrexed based regimens, 10 clinical studies which including 513 patients with advanced breast cancer were considered eligible for inclusion. For second line pemetrexed based chemotherapy, 5 clinical studies which including 281 patients with advanced breast cancer were considered eligible. Systemic analysis suggested that, in all patients, pooled RR was 32.6% (167/513) in pemetrexed based first line regimens, and 13.9 % (39/281) in pemetrexed based second line regimens. Major adverse effects were neutropenia, leukopenia, fatigue, and anemia in pemetrexed based first line treatment; and lymphopenia, neutropenia, leukopenia, as well as anemia in second line chemotherapy. One treatment related death occurred with pemetrexed based second line treatment. Conclusion: This systemic analysis suggests that pemetrexed based first line regimens are associated with a reasonable response rate and acceptable toxicity, however with low response rate for treating patients with metastatic breast cancer when is used in the second line.

• 한국간담췌외과학회지
• /
• 제27권2호
• /
• pp.172-179
• /
• 2023

Backgrounds/Aims: Cancer stigma (CS), a self-inflicted sense of hopelessness, has been identified as a major factor affecting cancer patients' outcomes. However, few studies have investigated the CS-related outcomes in hepatobiliary and pancreatic (HBP) cancer. Thus, the aim of this study was to investigate effects of CS on quality of life (QoL) of HBP cancer. Methods: From 2017 to 2018, 73 patients who underwent curative surgery for HBP tumor at a single intuitive were enrolled prospectively. The QoL was measured using the European Organization for Research and Treatment of Cancer QoL score, and CS was evaluated in three categories, "impossibility of recovery," "cancer stereotypes," and "social discrimination." the stigma was defined by higher scores of attitudes compared with the median value. Results: The stigma group showed a lower QoL (-17.67, 95% confidence interval [CI]: -26.75 to 8.60, p < 0.001) than the no stigma group. Similarly, most function and symptoms of the stigma group showed worse results than the no stigma group. The difference in function scores between the two groups according to CS was highest in cognitive function (-21.20, 95% CI: -30.36 to 12.04, p < 0.001). Fatigue showed the largest difference between the two groups at 22.84 (95% CI: 12.88-32.07, p < 0.001) and was the most severe symptom in stigma group. Conclusions: CS was an important negative factor affecting the QoL, function, and symptoms of HBP cancer patients. Therefore, appropriate management of CS is crucial for improved postoperative QoL.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권11호
• /
• pp.5587-5591
• /
• 2012

Objective: This study was performed to evaluated the efficacy and safety of continuous infusional paclitaxel and 5-Fu as first-line chemotherapy in patients with advanced esophageal squamous cell cancer (ESCC). Methods: A total of 22 patients with advanced esophageal squamous cell cancer with no indications for surgery and radiation therapy, or recurrent patients were enrolled from October 2008 to November 2010. All were treated with PTX 20 $mg/m^2$ was administered through a 16 hours continuous intravenous infusion on days 1 to 3, 8 and 9. DDP 3.75 $mg/m^2$ was given on days 1 to 4 and 8 to 11, continuous infusional 5-FU over 24-hours on days 1 to 5 and 8 to 12 at a dose of 375 $mg/m^2$, and folacin 60 mg orally synchronized with 5-Fu. The treatment was repeated every 21 days for at least two cycles. Results: 22 cases of all enrolled patients could be evaluated for the effect of treatment: 2 cases were CR, 9 cases PR, 5 cases SD and 2 cases PD, giving an overall response rate of 68.2%(15/22). The median time to progression was 7.0 months. The adverse reactions related to chemotherapy were tolerable; the most common toxic effects were marrow depression, alopecia, and fatigue. Conclusion: Low-dose continuous infusional PTX over 16-hours and 5-fu over 24-hours is a promising regimen with good tolerability in treating patients with advanced esophageal squamous cell cancer.

• 한국산학기술학회논문지
• /
• 제17권12호
• /
• pp.307-315
• /
• 2016

의료 기술의 발달은 암 환자의 생존율을 크게 향상시켰으며, 암치료는 종료되었지만 암생존자들은 지속되는 신체적, 심리적, 사회적 문제로 고통 받고 있다. 따라서 암생존자들이 경험하는 문제에 총체적으로 접근하기 위해서는 다양한 통합 재활프로그램이 개발되어야 한다. 본 연구는 암생존자를 위한 재활 프로그램의 내용 및 구성을 확인하고 재활의 효과를 분석하여 향후 통합재활프로그램 개발의 자료로 사용하고자 한다. 문헌검토를 통해 검색된 13개의 연구 논문을 고찰한 결과 암생존자를 위한 재활 프로그램은 운동, 심리사회적, 통합 프로그램으로 분류되었으며, 운동 프로그램은 신체 기능 향상과 피로, 이차암 또는 암 재발과 관련된 호르몬의 변화를 통해 재활의 효과를 측정하였다. 심리사회 프로그램은 삶의 질, 우울, 불안 등과 같은 정서의 변화, 긍정적 자기 변화를 표현하는 외상 후 성장으로 효과를 측정하였고 긍정적인 결과를 보여주었다. 통합재활프로그램은 신체적, 심리사회적 측면을 모두 향상시켰다. 향후 암생존자를 위한 재활 프로그램은 신체적, 심리사회적 측면뿐만 아니라 직업 재활 측면까지 고려되어야 하며 암생존자의 다양성에 맞추어 프로그램을 탄력적으로 적용할 수 있도록 구성되어야 한다.

• Journal of Hospice and Palliative Care
• /
• 제13권2호
• /
• pp.98-108
• /
• 2010

목적: 본 연구는 암환자의 삶의 질, 피로 정도를 확인하고 삶의 질과 피로와의 관계를 파악함으로써 암환자의 삶의 질 향상을 위한 간호중재 개발에 필요한 기초자료를 제공하고자 실시되었다. 방법: 대상자는 D, Y, A시에 소재한 대학부속병원에서 암 진단을 받고 치료를 받는 입원환자 94명을 대상으로 하였으며, 자료는 2007년 5월 8일부터 8월 10일까지 구조화된 설명지로 수집하였다. 연구도구로는 피로는 FACIT (Functional Assessment of Chronic Illness Therapy, www.facit.org)에서 개발한 측정도구인 한국어판 FACIT-Fatigue Scale인 13개 문항과 삶의 질은 FACIT에서 개발한 한국어판 FACT-G (Version 4) 27개 문항을 이용하였다. 수집된 자료는 SPSS Win 12.0을 이용하여 실수와 백분율, 평균과 표준편차, t-test와 ANOVA, Pearson correlation coefficients로 분석하였다. 결과: 암환자의 피로 정도는 22.48로 중간 정도의 상태를 보였다. 암환자의 삶의 질 정도는 평균 55.52로 중간 정도였고, 삶의 질의 하위영역에서는 신체적 영역이 평균 15.96로 가장 높았고, 기능적 영역이 평균 11.34로 가장 낮게 나타났다. 암환자의 피로는 피로의 정도에 차이를 보인 일반적 특성은 없었으며, 피로의 정도에 차이를 보인 질병관련 특성은 치료형태(F=3.216, P< 0.05), 체중변화(F=9.094, P<0.001), 일상생활 수행상태(F=7.297, P<0.001), 운동(F=5.919, P<0.05), 수면(F= 4.546, P<0.05) 등이었다. 암환자의 삶의 질 정도에 차이를 보인 질병관련 특성은 치료목적(F=4.392, p<0.05), 체중변화(F=23.118, P<0.001), 일상생활 수행상태(F= 9.886, P<0.001), 운동(F=7.699, P<0.001), 수면(F=5.893, P<0.001)이었다. 암환자의 삶의 질은 피로(r=-0.752, P<0.001)와 유의한 역 상관관계가 있는 것으로 나타났다. 피로는 삶의 질 하부 영역 중 신체적 영역(r=-0.834, P<0.001), 정서적 영역(r=-0.610, P<0.001), 기능적 영역(r=-0.560, P<0.001)과 유의한 역 상관관계를 보였다. 결론: 암환자의 삶의 질에 피로가 중요한 변수임을 확인하였고, 암환자의 삶의 질과 피로는 유의한 역 상관관계가 있음도 확인하였다. 이상의 연구결과를 기초로 암환자의 전반적인 삶의 질과 하부영역별 삶의 질을 향상시키고 피로를 감소시킬 수 있는 간호중재 프로그램을 우선적으로 개발하고 적용해야 할 것이다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권11호
• /
• pp.4791-4795
• /
• 2015

Purpose: This study was conducted to observe the efficacy and safety of pemetrexed based chemotherapy in treating patients with locally advanced or metastatic cancers as first-line, second-line or third-line therapy. Materials and Methods: From May 2011 to January 2015, we recruited 29 patients with advanced breast cancer, 19 patients with advanced ovary cancer, 17 patients with advanced esophageal cancer,5 patients with advanced gallbladder cancer,5 patients with advanced cervical cancer and 1 patient with advanced tongue cancer in Jiangsu Cancer Hospital and Research Institute.All of them were pathologically confirmed and treated with pemetrexed based chemotherapy. After two cycles of treatment,efficacy and safety can be evaluated. Results: For pemetrexed based regimens,including 76 patients with 6 kinds of advanced cancer were considered eligible for inclusion. Complete remission represents CR, partial remission represents PR, stable disease represents SD, progressive disease represents PD. Among 29 patients with advanced breast cancer, 4 patients chose pemetrexed based regimens as second-line treatment,1 of them was PR,the other 3 got SD. The last 25 patients made use of this chemotherapy as third-line treatment, except one patient could not be assessed, 2 of them got PR,6 of them got SD,the remaining 16 of them finally were PD.19 patients with advanced ovary cancer,5 patients used this regimens as second-line treatment, 3 of them got PD,the remaining patients got SD, respectively. The last 14 patients made use of pemetrexed based regimens as third-line treatment,. RR (CR+PR) was 28.5%. Among 17 patients with advanced esophageal cancer, 2 patients made use of pemetrexed based regimens as first-line treatment,both of them got PR.4 of them used this chemotherapy as second-line regimen, except 2 patients could not be assessed,the remaining 2 was PD at last. The last 11 patients was third-line users, RR (CR+PR) was 18.2%. Among 5 patients with advanced gallbladder cancer, pemetrexed based regimens was used in 1 patient as first-line treatment and 1 patient as second-line treatment. The curative effect was SD and PD, respectively. 3 patients accepted pemetrexed based regimens as third-line treatment, 2 of them got PD as results and another was SD. Among 5 patients with advanced cervical cancer, just 1 patient adopted pemetrexed based regimens as first-line treatment, whose curative effect was PR.2 patients chose this chemotherapy regimens as second-line treatment. Both of them got PD as their consequence. The last 2 patients made use of the regimens as third-line treatment, the effect of them was PD and SD, respectively. The one who with advanced tongue cancer, pemetrexed based regimens was used as second-line treatment, and the consequence was PD. About 71.1% patients experienced bone marrow suppression. Among them, 5 patients reached 4 grade. Other toxicity of pemetrexed were neurotoxicity, fatigue, diarrhea, dysphagia and vomiting. No treatment related death occurred with pemetrexed-based treatment. Conclusions: Pemetrexed based chemotherapy has considerable effect in patients with advanced cancers such as breast cancer,esophageal cancer and ovary cancer. More randomly clinical trials are needed to verify the results.

• 종양간호연구
• /
• 제4권1호
• /
• pp.16-25
• /
• 2004

The purpose of this study is to provide the basic data to improve the QOL in patients suffering from female cancers. Subjects of this study were consisted 255 persons who admitted or visited three university hospitals. The instruments used for this study included "the Quality Of Life Scale(QOL)" developed by National Conference on Cancer Nursing and successively amended by Kwon(1990), "Anger in" developed by Spielberger(1988) and successively amended by Chon(1997). The collected data were analyzed using a SPSS 11.0 for PC. To find out significant factors of Anger in & QOL in patients with Female Cancer patients, Frequency, Percentage, t-test, ANOVA, Scheffe-test, Pearson's correlation coefficients were conducted. The main findings : Anger in score was a little low & QOL score was middle. Several characteristics of the subjects were identified to differenti ate the "Anger in" and "QOL". Age status(F=2.64, p=0.05), education status(F=2.73, p=0.04), Health insurance(t=2.27, p=0.00) and cancer insurance status(t=2.97, p=0.00) was significant factors of the "Anger in". Education status(F=2.64 p=0.05), Occupation status (t=2.90, p=0.00), Monthly income (F=3.23 p=0.01), Stage of disease(F=9.23 p=0.00), Perceived health status(F=73.61 p=0.00), Perceived fatigue status(F=11.26 p=0.00) was significant factors of the "QOL". In conclusion, Anger in score was a little low & QOL sore was moderate. The degree of Anger in and quality of life were significantly negative correlated. Therefore, It is needed strategies for intervention of 'Anger in' to improve the QOL in female cancer patients. The significant characteristics of related to "anger in" & QOL should consider in sociopsychogical nursing intervention.

• 대한간호학회지
• /
• 제39권5호
• /
• pp.683-692
• /
• 2009

Purpose: The purpose of this study was to identify cancer-related symptom clusters and to validate the conceptual meanings of the revealed symptom clusters in patients with hepatocellular carcinoma. Methods: This study was a cross-sectional survey and methodological study. Patients with hepatocellular carcinoma (N=194) were recruited from a medical center in Seoul. The 20-item Symptom Checklist was used to assess patients' symptom severity. Selected symptoms were factored using principal-axis factoring with varimax rotation. To validate the revealed symptom clusters, the statistical differences were analyzed by status of patients' performance status, Child-Pugh classification, and mood state among symptom clusters. Results: Fatigue was the most prevalent symptom (97.4%), followed by lack of energy and stomach discomfort. Patients' symptom severity ratings fit a four-factor solution that explained 61.04% of the variance. These four factors were named pain-appetite cluster, fatigue cluster, itching-constipation cluster, and gastrointestinal cluster. The revealed symptom clusters were significantly different for patient performance status (ECOG-PSR), Child-Pugh class, anxiety, and depression. Conclusion: Knowing these symptom clusters may help nurses to understand reasonable mechanisms for the aggregation of symptoms. Efficient symptom management of disease-related and treatment-related symptoms is critical in promoting physical and emotional status in patients with hepatocellular carcinoma.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권4호
• /
• pp.1581-1584
• /
• 2014

Background: The overall prognosis for cancers of unknown primary (CUP) is poor, median overall survival (OS) being 6-12 months. We evaluated our multicentric retrospective experience for CUP administered docetaxel and cisplatin combination therapy. Materials and Methods: A total of 29 patients that were pathologically confirmed subtypes of CUP were included in the study. The combination of docetaxel ($75mg/m^2$, day 1) and cisplatin ($75mg/m^2$, day 1) was performed as a first line regimen every 21 days. Results: The median age was 51 (range: 27-68). Some 17 patients had multimetastatic disease on the inital diagnosis. Histopathological diagnoses were well-moderate differentiated adenocarcinoma (51.7%), undifferentiated carcinoma (27.6%), squamous cell cancer (13.8%), mucoepidermoid carcinoma (3.4%) and neuroendocrine differentiated carcinoma (3.4%). Median number of cycles was 3 (range: 1-6). Objective response rate was 37.9% and clinical benefit was 58.6%. Median progression free survival (PFS) and overall survival (OS) were 6 months (range: 4.3-7.7 months) and 16 months (range: 8.1-30.9 months), respectively. Fourteen patients (60.8%) were treated in a second line setting. There was no treatment related death. Most common toxicities were nausia-vomiting (44.6%) and fatigue (34.7%), serious cases (grade 3/4) suffering nausia-vomiting (10.3%), neutropenia (13.8%) and febrile neutropenia (n=1). Conclusion: The combination of cisplatin and docetaxel is an effective regimen for selected patients with CUP.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권11호
• /
• pp.4781-4786
• /
• 2015

Siberian ginseng (Eleutherococcus senticosus) is used primarily as an adaptogen herb and also for its immune stimulant properties in Western herbal medicine. Another closely related species used in East Asian medicine systems i.e. Kampo, TCM (Manchuria, Korea, Japan and Ainu of Hokkaido) and also called Siberian ginseng (Acanthopanax senticosus) also displays immune-stimulant and anti-cancer properties. These may affect tumour growth and also provide an anti-fatigue effect for cancer patients, in particular for those suffering from lung cancer. There is some evidence that a carbohydrate in Siberian ginseng may possess not only immune stimulatory but also anti-tumour effects and also display other various anti-cancer properties. Our study aimed to determine the inhibitory and also proliferative effects of a methanol plant extract of Siberan ginseng (E. senticosus) on various cancer and normal cell lines including: A-549 (small cell lung cancer), XWLC-05 (Yunnan lung cancer cell line), CNE (human nasopharyngeal carcinoma cell line), HCT-116 (human colon cancer) and Beas-2b (human lung epithelial). These cell lines were treated with an extract from E. senticosus that was evaporated and reconstituted in DMSO. Treatment of A-549 (small cell lung cancer) cells with E. senticosus methanolic extract showed a concentration-dependent inhibitory trend from $12.5-50{\mu}g/mL$, and then a plateau, whereas at 12.5 and $25{\mu}g/mL$, there is a slight growth suppression in QBC-939 cells, but then a steady suppression from 50, 100 and $200{\mu}g/mL$. Further, in XWLC-05 (Yunnan lung cancer cell line), E. senticosus methanolic extract displayed an inhibitory effect which plateaued with increasing dosage. Next, in CNE (human nasopharyngeal carcinoma cell line) there was a dose dependent proliferative response, whereas in Beas-2 (human lung epithelial cell line), an inhibitory effect. Finally in colon cancer cell line (HCT-116) we observed an initially weak inhibitory effect and then plateau.